Echo Life Sciences Fund, LP
Raised
$12M
Investors
9
Min Invest
None stated
Is this your company or fund? Claim this page free.
AltStreet Analysis
·Generated from EDGAR primary sources
Echo Life Sciences Fund, LP is a Delaware limited partnership that has raised $12.3M from 9 investors under Rule 506(b) and Section 3(c)(1). The fund, managed by Echo Investment Capital, LLC with executive officer Michael Kanady, focuses on longevity biotech investments. This is an amended filing with no minimum investment disclosed.
This longevity biotech fund follows a typical private placement structure using 506(b) exemption, indicating pre-existing relationships with accredited investors. With an average check size of approximately $1.4M across 9 investors, the fund sits in the emerging manager tier for specialized life sciences strategies focused on aging and longevity research.
Data Flags
Critical Disclosures
What the filings and the regulators have said about this entity that a reader should know first. Each line links to its source. The history, the same event across other issuers, and alerts are in the terminal.
Reporting lapsed · Form D · last filing July 7, 2023
Offering declared to continue beyond a year; annual amendment 13+ months overdue An issuer that stops filing is the case the going-concern flag cannot catch: the report that would have carried it was never filed.
EDGAR Filing Data
Form D — Primary Source
View on SEC.govFilings on Record
Every filing AltStreet's ledger holds for this CIK, newest first. Each opens the SEC archive folder.
Capital Raise Timeline
3 Form D filings from Aug 9, 2021 to Jul 7, 2023, the latest a D/A.
In the Terminal
Filing events
0
none on file
Critical / warning
0 / 0
0 watch · 0 info
Statements extracted
0
none on file
NAV prints
0
none on file
Offering chains
1
dark
Investor
- 1 offering timeline: velocity, share raised, first-sale lag, stalled flags
Pro
- This issuer against its cohort: rank by velocity and share raised among offerings filed the same quarter
- The same events, statements and NAV moves across every issuer, screenable, with unlimited watches and CSV
Counts and dates above are the free record. The values, the series and the comparisons are the seat. Loading your view…
Related Persons (Form D)
Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.
Item 3 changed on the Form D filed 2023-07-07: 0 related persons added and 1 removed against the filing of 2022-07-14; 3 now listed. The names are in the Terminal feed.
n/a Echo O-Bio Fund I GP, LLC
Promoter · Oklahoma City, OK
n/a Echo Investment Capital, LLC
Executive Officer · Oklahoma City, OK
Michael Kanady
Executive Officer · Oklahoma City, OK
Questions About Echo Life Sciences Fund, LP
Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.
What is Echo Life Sciences Fund, LP?
Echo Life Sciences Fund, LP is a Delaware limited partnership that filed a Form D with the SEC on July 7, 2023 as a venture capital fund. The filing claims Rule 506(b), Section 3(c), Section 3(c)(1) for an offering of pooled investment fund interests. AltStreet links the issuer to Echo Life Sciences Fund, LP.
Is Echo Life Sciences Fund, LP legit?
AltStreet does not rate legitimacy; it reports the public record. Echo Life Sciences Fund, LP filed a Form D with the SEC on July 7, 2023 claiming Rule 506(b), Section 3(c), Section 3(c)(1). A Form D is a notice of an exempt offering, not a review or approval of it. The newest notice reports $12,309,191 sold to 9 investors. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. The issuer is linked to Echo Life Sciences Fund, LP, which AltStreet has reviewed. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.
Is Echo Life Sciences Fund, LP registered with or approved by the SEC?
No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that Echo Life Sciences Fund, LP claimed Rule 506(b), Section 3(c), Section 3(c)(1) and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.
How much has Echo Life Sciences Fund, LP raised?
Echo Life Sciences Fund, LP reported $12,309,191 sold from 9 investors of a $50,000,000 total offering as of the Form D filed July 7, 2023.
Who can invest in Echo Life Sciences Fund, LP?
The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. Because the fund also relies on Section 3(c)(1), it may have no more than 100 beneficial owners. The filing reports no non-accredited investors. The filing lists the minimum investment as $0, meaning no minimum was stated.
What is the minimum investment in Echo Life Sciences Fund, LP?
The Form D lists the minimum investment as $0, which means the issuer did not state a minimum on the form. The offering documents, not the Form D, set the actual subscription terms.
Who is selling Echo Life Sciences Fund, LP and how are they paid?
The Form D names no recipient of sales compensation, which usually means the issuer or its affiliates are placing the securities directly.
Who is behind Echo Life Sciences Fund, LP?
The Form D lists 3 related persons: Echo O-Bio Fund I GP, LLC, promoter (General Partner); Echo Investment Capital, LLC, executive officer (Sponsor); Michael Christian Kanady, executive officer. Form D Item 3 requires executive officers, directors, and promoters of the issuer to be listed.
Where is Echo Life Sciences Fund, LP located?
The issuer's address on its SEC filings is 120 Robert S. Kerr, Suite 701, Oklahoma City, OK 73102. Its phone number of record is 405-225-2380. It is organized under the laws of Delaware.
How long is the Echo Life Sciences Fund, LP offering open?
The issuer indicated that the offering is intended to last more than one year. An issuer must amend its Form D annually while a continuing offering stays open; 2 amendments are on record for this CIK.
How large is Echo Life Sciences Fund, LP?
The issuer declined to disclose its revenue range on the Form D, which the form permits.
Is this your company or fund?
Free claim: add your contact details, website, team and a description to this page. The filed facts stay as filed.
Platform verification: the separate analyst-reviewed program for platforms, with right of reply and a document library.
Data Methodology
Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.